Live feed21:45:00·180dPRReleasevia QuantisnowORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025ByQuantisnow·Wall Street's wire, on your screen.ORIC· Oric Pharmaceuticals Inc.Health Care
